SCHEMBL20239258

SCHEMBL20239258

CN(C(=O)O)S(=O)(=O)Cc1ccc(Oc2cc(C#N)nc(C3CC3)n2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4B Q07343 1/20 0.34
PDE4D Q08499 1/20 0.34
MTNR1A P48039 1/20 0.32
MTNR1B P49286 1/20 0.32
CYP2C9 P11712 1/20 0.32
P2RY12 Q9H244 1/20 0.32
DPP4 P27487 1/20 0.31
NAPEPLD Q6IQ20 1/20 0.31
RORC P51449 1/20 0.31
PTGDR2 Q9Y5Y4 1/20 0.31
LMNA P02545 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31
TSHR P16473 1/20 0.31
MAPK1 P28482 1/20 0.31
CASP1 P29466 1/20 0.31
CASP7 P55210 1/20 0.31
HTT P42858 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20252434 0.88 DPP4 (0.33) PDE4BPDE4DDPP4
SCHEMBL18249760 0.87 PDE4B (0.39) PDE4BPDE4DMTNR1AMTNR1BNAPEPLD
SCHEMBL16738672 0.85 PDE2A (0.36) CYP2C9RORCLMNAALDH1A1KDM4E
SCHEMBL20239306 0.85 PDE4B (0.34) PDE4BPDE4DMTNR1AMTNR1BCYP2C9
SCHEMBL20239134 0.83 PTPN1 (0.33) LMNAALDH1A1HTTSMN1; SMN2SCN9A
SCHEMBL20239142 0.83 ALDH1A1 (0.36) CYP2C9ALDH1A1MAPTHPGDTSHR
SCHEMBL20239283 0.83 SMN1; SMN2 (0.34) PDE4BLMNAALDH1A1KDM4EMAPT
SCHEMBL20239238 0.82 KDM4E (0.35) PDE4BLMNAALDH1A1KDM4EMAPT
SCHEMBL20252430 0.76 SMN1; SMN2 (0.36) PDE4BPDE4DALDH1A1SMN1; SMN2
SCHEMBL21986281 0.74 GPR119 (0.32) PDE4BPDE4DLMNAALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT PDE4B 1093/4885PDE4D 2112/4885MTNR1A 2681/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT PDE4B 1262/4885PDE4D 2443/4885MTNR1A 1948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.